Exelixis, Inc. (EXEL)

Market Cap	10.52B
Revenue (ttm)	2.23B
Net Income (ttm)	602.30M
Shares Out	269.20M
EPS (ttm)	2.08
PE Ratio	18.81
Forward PE	14.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,620,548
Open	37.78
Previous Close	37.70
Day's Range	37.57 - 39.09
52-Week Range	25.17 - 49.62
Beta	0.32
Analysts	Buy
Price Target	43.65 (+11.72%)
Earnings Date	Oct 28, 2025

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,147
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Analyst Summary

According to 21 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $43.65, which is an increase of 11.72% from the latest price.

Price Target

$43.65

(11.72% upside)

Analyst Consensus: Buy